All In Biotech

Drug Trial Radar · NCT05743075

A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 526 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

526

Actual

Start

Mar 10, 2023

Primary completion

Dec 6, 2024

Study completion Mar 7, 2025

Sponsor

Sponsor type
Industry
Collaborators
Laboratory Corporation of America
First posted
Feb 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical study, which aims to evaluate the efficacy, safety, and PK characteristics of Ensifentrine 3 mg twice daily (BID) for 24 weeks treatment of moderate to severe COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • EnsifentrineDrug

    A dual PDE3/PDE 4 inhibitor

  • PlaceboDrug

    Placebo solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12hTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 1st Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.